{"transactions":[{"id":692758,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":25346,"kind":"person","name":"Kelly-Gemmell Dorothy Elizabeth","position":1,"cik":"0002144542","reported_name":"Kelly-Gemmell Dorothy Elizabeth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-07T20:34:44.000Z","date":"2026-08-01","kind":"grant","planned":false,"acquired":true,"shares":40800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-third of the shares subject to the option will vest on each anniversary of the grant date."}],"balance_after":40800,"derivative":{"exercise_price":31.74,"exercise_date":"2027-08-01","expiration_date":"2036-08-01","underlying":"Common Stock","underlying_shares":40800},"source":{"system":"sec-edgar","filing":"0002144542-26-000004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000214454226000004/ownership.xml","form_type":"4"}},{"id":692757,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":25346,"kind":"person","name":"Kelly-Gemmell Dorothy Elizabeth","position":1,"cik":"0002144542","reported_name":"Kelly-Gemmell Dorothy Elizabeth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-08-07T20:34:44.000Z","date":"2026-08-01","kind":"grant","planned":false,"acquired":true,"shares":6333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award (\"RSU\") of common stock under the Issuer's 2024 Equity Incentive Plan.  One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award."}],"balance_after":6333,"source":{"system":"sec-edgar","filing":"0002144542-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000214454226000004/ownership.xml","form_type":"4"}},{"id":701313,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27973,"kind":"person","name":"Lian Brian","position":1,"cik":"0001614578","reported_name":"Lian Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-07-30T00:07:25.000Z","date":"2026-07-29","kind":"sale","planned":false,"acquired":false,"shares":148517,"price":33.3153,"value":4947888.4101,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.82 to $33.77, inclusive. The Reporting Person  undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote."}],"balance_after":2572441,"source":{"system":"sec-edgar","filing":"0001193125-26-324448","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526324448/ownership.xml","form_type":"4"}},{"id":701312,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27973,"kind":"person","name":"Lian Brian","position":1,"cik":"0001614578","reported_name":"Lian Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-07-30T00:07:25.000Z","date":"2026-07-28","kind":"grant","planned":false,"acquired":true,"shares":221667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal."}],"balance_after":2720958,"source":{"system":"sec-edgar","filing":"0001193125-26-324448","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526324448/ownership.xml","form_type":"4"}},{"id":701311,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27972,"kind":"person","name":"Mancini Marianna","position":1,"cik":"0001838112","reported_name":"Mancini Marianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-07-30T00:06:00.000Z","date":"2026-07-29","kind":"sale","planned":false,"acquired":false,"shares":18217,"price":33.4652,"value":609635.5484,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.28 to $33.805, inclusive. The Reporting Person  undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote."}],"balance_after":422760,"source":{"system":"sec-edgar","filing":"0001193125-26-324446","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526324446/ownership.xml","form_type":"4"}},{"id":701310,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27972,"kind":"person","name":"Mancini Marianna","position":1,"cik":"0001838112","reported_name":"Mancini Marianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-07-30T00:06:00.000Z","date":"2026-07-28","kind":"grant","planned":false,"acquired":true,"shares":31667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 120 shares acquired on May 20, 2026 pursuant to the Issuer's 2024 Employee Stock Purchase Plan."}],"balance_after":440977,"source":{"system":"sec-edgar","filing":"0001193125-26-324446","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526324446/ownership.xml","form_type":"4"}},{"id":701398,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-07-29T20:06:43.000Z","date":"2026-07-29","kind":"sale","planned":false,"acquired":false,"shares":21217,"price":33.4704,"value":710141.4768,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.30 to $33.805, inclusive. The Reporting Person  undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote."}],"balance_after":212204,"source":{"system":"sec-edgar","filing":"0001193125-26-324447","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000119312526324447/ownership.xml","form_type":"4"}},{"id":701397,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-07-29T20:06:43.000Z","date":"2026-07-28","kind":"grant","planned":false,"acquired":true,"shares":31667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 11,055 shares acquired on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Purchase Plan and 808 shares acquired on May 20, 2026 pursuant to the Issuer's 2024 Employee Stock Purchase Plan"}],"balance_after":233421,"source":{"system":"sec-edgar","filing":"0001193125-26-324447","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000119312526324447/ownership.xml","form_type":"4"}},{"id":750859,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":41623,"kind":"person","name":"Chen Hubert C","position":1,"cik":"0001622297","reported_name":"Chen Hubert C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-03T23:44:43.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":190000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vested immediately, and 25% of the shares subject to the option will vest on each one-year anniversary of the grant date over the next three years."}],"balance_after":190000,"derivative":{"exercise_price":31.27,"expiration_date":"2036-06-01","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0001193125-26-256039","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526256039/ownership.xml","form_type":"4"}},{"id":850276,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":61692,"kind":"person","name":"Aubuchon Neil William","position":1,"cik":"0002106781","reported_name":"Aubuchon Neil William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-03-10T22:20:39.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":4475,"price":33.5,"value":149912.5,"ownership":{"direct":true},"balance_after":4475,"source":{"system":"sec-edgar","filing":"0001193125-26-100581","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526100581/ownership.xml","form_type":"4"}},{"id":931023,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":61692,"kind":"person","name":"Aubuchon Neil William","position":1,"cik":"0002106781","reported_name":"Aubuchon Neil William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-27T00:57:19.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option will vest immediately, and 25% of the shares subject to the option will vest on each one-year anniversary of the grant date over the next three years."}],"balance_after":180000,"derivative":{"exercise_price":31.76,"expiration_date":"2036-01-12","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001193125-26-023030","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526023030/ownership.xml","form_type":"4"}},{"id":950003,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27972,"kind":"person","name":"Mancini Marianna","position":1,"cik":"0001838112","reported_name":"Mancini Marianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T01:31:16.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":91000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"25% of the shares subject to the option will vest on each anniversary of the grant date."}],"balance_after":91000,"derivative":{"exercise_price":35.42,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":91000},"source":{"system":"sec-edgar","filing":"0001193125-26-003115","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526003115/ownership.xml","form_type":"4"}},{"id":950002,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27972,"kind":"person","name":"Mancini Marianna","position":1,"cik":"0001838112","reported_name":"Mancini Marianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-06T01:31:16.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":1600,"price":35.0731,"value":56116.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.88 to $35.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":409190,"source":{"system":"sec-edgar","filing":"0001193125-26-003115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526003115/ownership.xml","form_type":"4"}},{"id":950001,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27972,"kind":"person","name":"Mancini Marianna","position":1,"cik":"0001838112","reported_name":"Mancini Marianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-06T01:31:16.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":10500,"price":34.2193,"value":359302.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.87 to $34.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":410790,"source":{"system":"sec-edgar","filing":"0001193125-26-003115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526003115/ownership.xml","form_type":"4"}},{"id":950000,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27972,"kind":"person","name":"Mancini Marianna","position":1,"cik":"0001838112","reported_name":"Mancini Marianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-06T01:31:16.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":13600,"price":33.3732,"value":453875.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.87 to $33.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":421290,"source":{"system":"sec-edgar","filing":"0001193125-26-003115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526003115/ownership.xml","form_type":"4"}},{"id":949999,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27972,"kind":"person","name":"Mancini Marianna","position":1,"cik":"0001838112","reported_name":"Mancini Marianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-06T01:31:16.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":31961,"price":32.2928,"value":1032110.1808,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.87 to $32.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":434890,"source":{"system":"sec-edgar","filing":"0001193125-26-003115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526003115/ownership.xml","form_type":"4"}},{"id":949998,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27972,"kind":"person","name":"Mancini Marianna","position":1,"cik":"0001838112","reported_name":"Mancini Marianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-06T01:31:16.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":32049,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on January 2, 2026, upon the achievement of a non-financial performance goal and a second performance restricted stock unit award that was granted on January 3, 2025, 1.665% of which vested on January 2, 2026, upon the partial achievement of a non-financial performance goal."}],"balance_after":466851,"source":{"system":"sec-edgar","filing":"0001193125-26-003115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526003115/ownership.xml","form_type":"4"}},{"id":949997,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27972,"kind":"person","name":"Mancini Marianna","position":1,"cik":"0001838112","reported_name":"Mancini Marianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-06T01:31:16.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":41000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award (\"RSU\") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 11,111 shares acquired on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Purchase Plan and 108 shares acquired on May 20, 2025 and 116 shares acquired on November 20, 2025 both pursuant to the Issuer's 2024 Employee Stock Purchase Plan."}],"balance_after":434802,"source":{"system":"sec-edgar","filing":"0001193125-26-003115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526003115/ownership.xml","form_type":"4"}},{"id":949996,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27973,"kind":"person","name":"Lian Brian","position":1,"cik":"0001614578","reported_name":"Lian Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T01:28:24.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":176300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"25% of the shares subject to the option will vest on each anniversary of the grant date."}],"balance_after":176300,"derivative":{"exercise_price":35.42,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":176300},"source":{"system":"sec-edgar","filing":"0001193125-26-003113","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526003113/ownership.xml","form_type":"4"}},{"id":949995,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27973,"kind":"person","name":"Lian Brian","position":1,"cik":"0001614578","reported_name":"Lian Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-06T01:28:24.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":6400,"price":35.0661,"value":224423.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.88 to $35.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":2499291,"source":{"system":"sec-edgar","filing":"0001193125-26-003113","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526003113/ownership.xml","form_type":"4"}},{"id":949994,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27973,"kind":"person","name":"Lian Brian","position":1,"cik":"0001614578","reported_name":"Lian Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-06T01:28:24.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":41276,"price":34.2184,"value":1412398.6784,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.87 to $34.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":2505691,"source":{"system":"sec-edgar","filing":"0001193125-26-003113","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526003113/ownership.xml","form_type":"4"}},{"id":949993,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27973,"kind":"person","name":"Lian Brian","position":1,"cik":"0001614578","reported_name":"Lian Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-06T01:28:24.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":53279,"price":33.3765,"value":1778266.5435,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.87 to $33.865, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":2546967,"source":{"system":"sec-edgar","filing":"0001193125-26-003113","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526003113/ownership.xml","form_type":"4"}},{"id":949992,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27973,"kind":"person","name":"Lian Brian","position":1,"cik":"0001614578","reported_name":"Lian Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-06T01:28:24.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":132454,"price":32.2907,"value":4277032.3778,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.87 to $32.865, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":2600246,"source":{"system":"sec-edgar","filing":"0001193125-26-003113","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526003113/ownership.xml","form_type":"4"}},{"id":949991,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27973,"kind":"person","name":"Lian Brian","position":1,"cik":"0001614578","reported_name":"Lian Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-06T01:28:24.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":224080,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on January 2, 2026. upon the achievement of a non-financial performance goal and a second performance restricted stock unit award that was granted on January 3, 2025, 1.665% of which vested on January 2, 2026, upon the partial achievement of a non-financial performance goal."}],"balance_after":2732700,"source":{"system":"sec-edgar","filing":"0001193125-26-003113","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526003113/ownership.xml","form_type":"4"}},{"id":949990,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27973,"kind":"person","name":"Lian Brian","position":1,"cik":"0001614578","reported_name":"Lian Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-06T01:28:24.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":78400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award (\"RSU\") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 11,111 shares acquired on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Purchase Plan."}],"balance_after":2508620,"source":{"system":"sec-edgar","filing":"0001193125-26-003113","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526003113/ownership.xml","form_type":"4"}},{"id":950668,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":53388,"kind":"person","name":"FOEHR MATTHEW W","position":1,"cik":"0001237556","reported_name":"FOEHR MATTHEW W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T01:25:28.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":20400,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20400,"derivative":{"exercise_price":35.42,"exercise_date":"2027-01-02","expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":20400},"source":{"system":"sec-edgar","filing":"0001193125-26-003109","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1237556/000119312526003109/ownership.xml","form_type":"4"}},{"id":950667,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":53388,"kind":"person","name":"FOEHR MATTHEW W","position":1,"cik":"0001237556","reported_name":"FOEHR MATTHEW W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T01:25:28.000Z","date":"2026-01-02","kind":"exercise","planned":false,"acquired":false,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3.33,"exercise_date":"2017-01-04","expiration_date":"2026-01-04","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001193125-26-003109","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1237556/000119312526003109/ownership.xml","form_type":"4"}},{"id":950666,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":53388,"kind":"person","name":"FOEHR MATTHEW W","position":1,"cik":"0001237556","reported_name":"FOEHR MATTHEW W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-06T01:25:28.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":3150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents a restricted stock unit award (\"RSU\") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award."}],"balance_after":135186,"source":{"system":"sec-edgar","filing":"0001193125-26-003109","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1237556/000119312526003109/ownership.xml","form_type":"4"}},{"id":950665,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":53388,"kind":"person","name":"FOEHR MATTHEW W","position":1,"cik":"0001237556","reported_name":"FOEHR MATTHEW W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-06T01:25:28.000Z","date":"2026-01-02","kind":"sale","planned":false,"acquired":false,"shares":16000,"price":35.1059,"value":561694.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.94 to $35.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":132036,"source":{"system":"sec-edgar","filing":"0001193125-26-003109","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1237556/000119312526003109/ownership.xml","form_type":"4"}},{"id":950664,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":53388,"kind":"person","name":"FOEHR MATTHEW W","position":1,"cik":"0001237556","reported_name":"FOEHR MATTHEW W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-06T01:25:28.000Z","date":"2026-01-02","kind":"exercise","planned":false,"acquired":true,"shares":16000,"price":3.33,"value":53280.0,"ownership":{"direct":true},"balance_after":148036,"source":{"system":"sec-edgar","filing":"0001193125-26-003109","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237556/000119312526003109/ownership.xml","form_type":"4"}},{"id":949989,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T01:24:52.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":20400,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20400,"derivative":{"exercise_price":35.42,"exercise_date":"2027-01-02","expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":20400},"source":{"system":"sec-edgar","filing":"0001193125-26-003108","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526003108/ownership.xml","form_type":"4"}},{"id":949988,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-06T01:24:52.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":3150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award (\"RSU\") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award."}],"balance_after":4390,"source":{"system":"sec-edgar","filing":"0001193125-26-003108","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526003108/ownership.xml","form_type":"4"}},{"id":950706,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T20:31:41.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":91000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"25% of the shares subject to the option will vest on each anniversary of the grant date."}],"balance_after":91000,"derivative":{"exercise_price":35.42,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":91000},"source":{"system":"sec-edgar","filing":"0001193125-26-003116","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000119312526003116/ownership.xml","form_type":"4"}},{"id":950705,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-05T20:31:41.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":1500,"price":32.0887,"value":48133.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.88 to $35.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":189891,"source":{"system":"sec-edgar","filing":"0001193125-26-003116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000119312526003116/ownership.xml","form_type":"4"}},{"id":950704,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-05T20:31:41.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":10300,"price":34.2364,"value":352634.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.88 to $34.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":191371,"source":{"system":"sec-edgar","filing":"0001193125-26-003116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000119312526003116/ownership.xml","form_type":"4"}},{"id":950703,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-05T20:31:41.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":13900,"price":33.3828,"value":464020.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.88 to $33.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":201671,"source":{"system":"sec-edgar","filing":"0001193125-26-003116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000119312526003116/ownership.xml","form_type":"4"}},{"id":950702,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-05T20:31:41.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":31961,"price":32.295,"value":1032180.495,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.88 to $32.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":215571,"source":{"system":"sec-edgar","filing":"0001193125-26-003116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000119312526003116/ownership.xml","form_type":"4"}},{"id":950701,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-05T20:31:41.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":32049,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on January 2, 2026, upon the achievement of a non-financial performance goal and a second performance restricted stock unit award that was granted on January 3, 2025, 1.665% of which vested on January 2, 2026, upon the partial achievement of a non-financial performance goal."}],"balance_after":247532,"source":{"system":"sec-edgar","filing":"0001193125-26-003116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000119312526003116/ownership.xml","form_type":"4"}},{"id":950700,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-05T20:31:41.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":41000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award (\"RSU\") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 104 shares acquired on May 20, 2025 and 787 shares acquired on November 20, 2025 pursuant to the Issuer's 2024 Employee Stock Purchase Plan."}],"balance_after":215483,"source":{"system":"sec-edgar","filing":"0001193125-26-003116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000119312526003116/ownership.xml","form_type":"4"}},{"id":950683,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T20:26:57.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":20400,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20400,"derivative":{"exercise_price":35.42,"exercise_date":"2027-01-02","expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":20400},"source":{"system":"sec-edgar","filing":"0001193125-26-003112","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000119312526003112/ownership.xml","form_type":"4"}},{"id":950682,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-05T20:26:57.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":3150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award (\"RSU\") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award."}],"balance_after":12650,"source":{"system":"sec-edgar","filing":"0001193125-26-003112","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000119312526003112/ownership.xml","form_type":"4"}},{"id":950005,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70256,"kind":"person","name":"MACARTNEY LAWSON","position":1,"cik":"0001606831","reported_name":"MACARTNEY LAWSON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T20:26:27.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":20400,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20400,"derivative":{"exercise_price":35.42,"exercise_date":"2027-01-02","expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":20400},"source":{"system":"sec-edgar","filing":"0001193125-26-003111","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606831/000119312526003111/ownership.xml","form_type":"4"}},{"id":950004,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70256,"kind":"person","name":"MACARTNEY LAWSON","position":1,"cik":"0001606831","reported_name":"MACARTNEY LAWSON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-05T20:26:27.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":3150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award (\"RSU\") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award."}],"balance_after":51115,"source":{"system":"sec-edgar","filing":"0001193125-26-003111","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606831/000119312526003111/ownership.xml","form_type":"4"}},{"id":950422,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T20:25:57.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":20400,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20400,"derivative":{"exercise_price":35.42,"exercise_date":"2027-01-02","expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":20400},"source":{"system":"sec-edgar","filing":"0001193125-26-003110","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000119312526003110/ownership.xml","form_type":"4"}},{"id":950421,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-05T20:25:57.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":3150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award (\"RSU\") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award."}],"balance_after":33150,"source":{"system":"sec-edgar","filing":"0001193125-26-003110","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000119312526003110/ownership.xml","form_type":"4"}},{"id":1012434,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27972,"kind":"person","name":"Mancini Marianna","position":1,"cik":"0001838112","reported_name":"Mancini Marianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-10-28T23:51:22.000Z","date":"2025-10-28","kind":"sale","planned":false,"acquired":false,"shares":6185,"price":35.0027,"value":216491.6995,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.69 to $35.40, inclusive. The Reporting Person  undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote."}],"balance_after":382467,"source":{"system":"sec-edgar","filing":"0001193125-25-254304","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312525254304/ownership.xml","form_type":"4"}},{"id":1012433,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27972,"kind":"person","name":"Mancini Marianna","position":1,"cik":"0001838112","reported_name":"Mancini Marianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-10-28T23:51:22.000Z","date":"2025-10-27","kind":"grant","planned":false,"acquired":true,"shares":11117,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2025, 33.33% of which vested on October 27, 2025 upon the achievement of a non-financial performance goal and 15% of which vested also on October 27, 2025 upon the partial achievement of a non-financial performance goal."}],"balance_after":388652,"source":{"system":"sec-edgar","filing":"0001193125-25-254304","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312525254304/ownership.xml","form_type":"4"}},{"id":1012432,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27973,"kind":"person","name":"Lian Brian","position":1,"cik":"0001614578","reported_name":"Lian Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-10-28T23:48:53.000Z","date":"2025-10-28","kind":"sale","planned":false,"acquired":false,"shares":38989,"price":35.0079,"value":1364923.0131,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.66 to $35.48, inclusive. The Reporting Person  undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote."}],"balance_after":2419109,"source":{"system":"sec-edgar","filing":"0001193125-25-254299","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312525254299/ownership.xml","form_type":"4"}},{"id":1012431,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27973,"kind":"person","name":"Lian Brian","position":1,"cik":"0001614578","reported_name":"Lian Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-10-28T23:48:53.000Z","date":"2025-10-27","kind":"grant","planned":false,"acquired":true,"shares":70084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2025, 33.33% of which vested on October 27, 2025 upon the achievement of a non-financial performance goal and 15% of which vested also on October 27, 2025 upon the partial achievement of a non-financial performance goal."}],"balance_after":2458098,"source":{"system":"sec-edgar","filing":"0001193125-25-254299","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312525254299/ownership.xml","form_type":"4"}},{"id":1012484,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-28T19:49:42.000Z","date":"2025-10-27","kind":"exercise","planned":false,"acquired":false,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":4.88,"exercise_date":"2023-01-03","expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001193125-25-254300","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000119312525254300/ownership.xml","form_type":"4"}},{"id":1012483,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-28T19:49:42.000Z","date":"2025-10-27","kind":"exercise","planned":false,"acquired":false,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":5.8,"exercise_date":"2022-01-04","expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001193125-25-254300","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000119312525254300/ownership.xml","form_type":"4"}},{"id":1012482,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-28T19:49:42.000Z","date":"2025-10-27","kind":"exercise","planned":false,"acquired":false,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":4.48,"exercise_date":"2019-01-02","expiration_date":"2028-01-02","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001193125-25-254300","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000119312525254300/ownership.xml","form_type":"4"}},{"id":1012481,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-10-28T19:49:42.000Z","date":"2025-10-27","kind":"sale","planned":false,"acquired":false,"shares":60000,"price":35.5713,"value":2134278.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.02 to $35.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001193125-25-254300","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000119312525254300/ownership.xml","form_type":"4"}},{"id":1012480,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-10-28T19:49:42.000Z","date":"2025-10-27","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":4.88,"value":107360.0,"ownership":{"direct":true},"balance_after":90000,"source":{"system":"sec-edgar","filing":"0001193125-25-254300","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000119312525254300/ownership.xml","form_type":"4"}},{"id":1012479,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-10-28T19:49:42.000Z","date":"2025-10-27","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":5.8,"value":127600.0,"ownership":{"direct":true},"balance_after":68000,"source":{"system":"sec-edgar","filing":"0001193125-25-254300","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000119312525254300/ownership.xml","form_type":"4"}},{"id":1012478,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-10-28T19:49:42.000Z","date":"2025-10-27","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":4.48,"value":71680.0,"ownership":{"direct":true},"balance_after":46000,"source":{"system":"sec-edgar","filing":"0001193125-25-254300","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000119312525254300/ownership.xml","form_type":"4"}},{"id":1012522,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-10-28T19:47:49.000Z","date":"2025-10-28","kind":"sale","planned":false,"acquired":false,"shares":6185,"price":35.0009,"value":216480.5665,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.6525 to $35.3939, inclusive. The Reporting Person  undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote."}],"balance_after":173592,"source":{"system":"sec-edgar","filing":"0001193125-25-254298","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000119312525254298/ownership.xml","form_type":"4"}},{"id":1012521,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-10-28T19:47:49.000Z","date":"2025-10-27","kind":"grant","planned":false,"acquired":true,"shares":11117,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2025, 33.33% of which vested on October 27, 2025 upon the achievement of a non-financial performance goal and 15% of which vested also on October 27, 2025 upon the partial achievement of a non-financial performance goal."}],"balance_after":179777,"source":{"system":"sec-edgar","filing":"0001193125-25-254298","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000119312525254298/ownership.xml","form_type":"4"}},{"id":1091833,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27973,"kind":"person","name":"Lian Brian","position":1,"cik":"0001614578","reported_name":"Lian Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-07-03T19:31:13.000Z","date":"2025-07-03","kind":"sale","planned":false,"acquired":false,"shares":26889,"price":27.8044,"value":747632.5116,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to  the performance restricted stock unit award described in Footnote 1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.70 to $27.86, inclusive. The Reporting Person  undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote."}],"balance_after":2388014,"source":{"system":"sec-edgar","filing":"0000950170-25-093793","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025093793/ownership.xml","form_type":"4"}},{"id":1091832,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27973,"kind":"person","name":"Lian Brian","position":1,"cik":"0001614578","reported_name":"Lian Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-07-03T19:31:13.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":48333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2025, 33.33% of which vested on July 2, 2025 upon the achievement of a non-financial performance goal."}],"balance_after":2414903,"source":{"system":"sec-edgar","filing":"0000950170-25-093793","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025093793/ownership.xml","form_type":"4"}},{"id":1091831,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27972,"kind":"person","name":"Mancini Marianna","position":1,"cik":"0001838112","reported_name":"Mancini Marianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-07-03T19:30:32.000Z","date":"2025-07-03","kind":"sale","planned":false,"acquired":false,"shares":4266,"price":27.7714,"value":118472.7924,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.755 to $27.79, inclusive. The Reporting Person  undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote."}],"balance_after":377535,"source":{"system":"sec-edgar","filing":"0000950170-25-093791","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025093791/ownership.xml","form_type":"4"}},{"id":1091830,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27972,"kind":"person","name":"Mancini Marianna","position":1,"cik":"0001838112","reported_name":"Mancini Marianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-07-03T19:30:32.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":7667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2025, 33.33% of which vested on July 2, 2025 upon the achievement of a non-financial performance goal."}],"balance_after":381801,"source":{"system":"sec-edgar","filing":"0000950170-25-093791","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025093791/ownership.xml","form_type":"4"}},{"id":1092089,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-07-03T15:31:07.000Z","date":"2025-07-03","kind":"sale","planned":false,"acquired":false,"shares":4266,"price":27.761,"value":118428.426,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.72 to $27.785, inclusive. The Reporting Person  undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote."}],"balance_after":168660,"source":{"system":"sec-edgar","filing":"0000950170-25-093792","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017025093792/ownership.xml","form_type":"4"}},{"id":1092088,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-07-03T15:31:07.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":7667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2025, 33.33% of which vested on July 2, 2025 upon the achievement of a non-financial performance goal."}],"balance_after":172926,"source":{"system":"sec-edgar","filing":"0000950170-25-093792","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017025093792/ownership.xml","form_type":"4"}},{"id":1172439,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":53388,"kind":"person","name":"FOEHR MATTHEW W","position":1,"cik":"0001237556","reported_name":"FOEHR MATTHEW W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-14T23:26:34.000Z","date":"2025-04-11","kind":"exercise","planned":false,"acquired":false,"shares":20786,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":8,"exercise_date":"2016-05-26","expiration_date":"2025-04-28","underlying":"Common Stock","underlying_shares":20786},"source":{"system":"sec-edgar","filing":"0000950170-25-053867","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1237556/000095017025053867/ownership.xml","form_type":"4"}},{"id":1172438,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":53388,"kind":"person","name":"FOEHR MATTHEW W","position":1,"cik":"0001237556","reported_name":"FOEHR MATTHEW W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-04-14T23:26:34.000Z","date":"2025-04-11","kind":"exercise","planned":false,"acquired":true,"shares":20786,"price":8,"value":166288.0,"ownership":{"direct":true},"balance_after":132036,"source":{"system":"sec-edgar","filing":"0000950170-25-053867","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237556/000095017025053867/ownership.xml","form_type":"4"}},{"id":1175213,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-04-08T23:05:30.000Z","date":"2025-03-31","kind":"purchase","planned":false,"acquired":true,"shares":1240,"price":24.1474,"value":29942.776,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person's purchase of shares of the Issuer's common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 1,240 shares, with the Reporting Person's sale of shares of the Issuer's common stock at a price of $80.89 per share on October 25, 2024. The Reporting Person has, on a voluntary basis, made arrangements with the Issuer to pay $70,316.25 to the Issuer, representing the full amount of the profit realized in connection with the short-swing transaction, less transactions costs."}],"balance_after":1240,"source":{"system":"sec-edgar","filing":"0000950170-25-052255","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025052255/ownership.xml","form_type":"4/A","original_submission_date":"2025-04-02"}},{"id":1182545,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-04-02T22:29:36.000Z","date":"2025-03-31","kind":"purchase","planned":false,"acquired":true,"shares":1240,"price":24.1474,"value":29942.776,"ownership":{"direct":true},"balance_after":1240,"source":{"system":"sec-edgar","filing":"0000950170-25-049717","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025049717/ownership.xml","form_type":"4"}},{"id":1309713,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27973,"kind":"person","name":"Lian Brian","position":1,"cik":"0001614578","reported_name":"Lian Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-07T01:16:00.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":78300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the option will vest on each anniversary of the grant date."}],"balance_after":78300,"derivative":{"exercise_price":42.89,"exercise_date":"2026-01-03","expiration_date":"2035-01-03","underlying":"Common Stock","underlying_shares":78300},"source":{"system":"sec-edgar","filing":"0000950170-25-002487","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025002487/ownership.xml","form_type":"4"}},{"id":1309712,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27973,"kind":"person","name":"Lian Brian","position":1,"cik":"0001614578","reported_name":"Lian Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-01-07T01:16:00.000Z","date":"2025-01-06","kind":"sale","planned":false,"acquired":false,"shares":19000,"price":43.3169,"value":823021.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards and certain performance restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.19 to $43.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":2366570,"source":{"system":"sec-edgar","filing":"0000950170-25-002487","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025002487/ownership.xml","form_type":"4"}},{"id":1309711,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27973,"kind":"person","name":"Lian Brian","position":1,"cik":"0001614578","reported_name":"Lian Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-01-07T01:16:00.000Z","date":"2025-01-06","kind":"sale","planned":false,"acquired":false,"shares":175490,"price":42.6838,"value":7490580.062,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards and certain performance restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.19 to $43.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":2385570,"source":{"system":"sec-edgar","filing":"0000950170-25-002487","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025002487/ownership.xml","form_type":"4"}},{"id":1309710,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27973,"kind":"person","name":"Lian Brian","position":1,"cik":"0001614578","reported_name":"Lian Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-01-07T01:16:00.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":163333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2024, 33.33% of which vested on January 3, 2025 upon the achievement of a non-financial performance goal."}],"balance_after":2561060,"source":{"system":"sec-edgar","filing":"0000950170-25-002487","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025002487/ownership.xml","form_type":"4"}},{"id":1309709,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27973,"kind":"person","name":"Lian Brian","position":1,"cik":"0001614578","reported_name":"Lian Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-01-07T01:16:00.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":92800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award (\"RSU\") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award."}],"balance_after":2397727,"source":{"system":"sec-edgar","filing":"0000950170-25-002487","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025002487/ownership.xml","form_type":"4"}},{"id":1309708,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27972,"kind":"person","name":"Mancini Marianna","position":1,"cik":"0001838112","reported_name":"Mancini Marianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-07T01:15:41.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":37200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the option will vest on each anniversary of the grant date."}],"balance_after":37200,"derivative":{"exercise_price":42.89,"exercise_date":"2026-01-03","expiration_date":"2035-01-03","underlying":"Common Stock","underlying_shares":37200},"source":{"system":"sec-edgar","filing":"0000950170-25-002486","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025002486/ownership.xml","form_type":"4"}},{"id":1309707,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27972,"kind":"person","name":"Mancini Marianna","position":1,"cik":"0001838112","reported_name":"Mancini Marianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-01-07T01:15:41.000Z","date":"2025-01-06","kind":"sale","planned":false,"acquired":false,"shares":5100,"price":43.3165,"value":220914.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards and certain performance restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.20 to $43.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":374134,"source":{"system":"sec-edgar","filing":"0000950170-25-002486","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025002486/ownership.xml","form_type":"4"}},{"id":1309706,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27972,"kind":"person","name":"Mancini Marianna","position":1,"cik":"0001838112","reported_name":"Mancini Marianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-01-07T01:15:41.000Z","date":"2025-01-06","kind":"sale","planned":false,"acquired":false,"shares":49115,"price":42.6893,"value":2096684.9695,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards and certain performance restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.20 to $43.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":379234,"source":{"system":"sec-edgar","filing":"0000950170-25-002486","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025002486/ownership.xml","form_type":"4"}},{"id":1309705,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27972,"kind":"person","name":"Mancini Marianna","position":1,"cik":"0001838112","reported_name":"Mancini Marianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-01-07T01:15:41.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":21667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2024, 33.33% of which vested on January 3, 2025 upon the achievement of a non-financial performance goal."}],"balance_after":428349,"source":{"system":"sec-edgar","filing":"0000950170-25-002486","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025002486/ownership.xml","form_type":"4"}},{"id":1309704,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":27972,"kind":"person","name":"Mancini Marianna","position":1,"cik":"0001838112","reported_name":"Mancini Marianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-01-07T01:15:41.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":44533,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award (\"RSU\") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award."}],"balance_after":406682,"source":{"system":"sec-edgar","filing":"0000950170-25-002486","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025002486/ownership.xml","form_type":"4"}},{"id":1310123,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":53388,"kind":"person","name":"FOEHR MATTHEW W","position":1,"cik":"0001237556","reported_name":"FOEHR MATTHEW W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-07T01:12:34.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":18800,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":18800,"derivative":{"exercise_price":41.12,"exercise_date":"2026-01-02","expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":18800},"source":{"system":"sec-edgar","filing":"0000950170-25-002481","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237556/000095017025002481/ownership.xml","form_type":"4"}},{"id":1309699,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-07T01:11:54.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":18800,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":18800,"derivative":{"exercise_price":41.12,"exercise_date":"2026-01-02","expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":18800},"source":{"system":"sec-edgar","filing":"0000950170-25-002480","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025002480/ownership.xml","form_type":"4"}},{"id":1310144,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-06T20:14:45.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":37200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to the option will vest on each anniversary of the grant date."}],"balance_after":37200,"derivative":{"exercise_price":42.89,"exercise_date":"2026-01-03","expiration_date":"2035-01-03","underlying":"Common Stock","underlying_shares":37200},"source":{"system":"sec-edgar","filing":"0000950170-25-002485","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017025002485/ownership.xml","form_type":"4"}},{"id":1310143,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-01-06T20:14:45.000Z","date":"2025-01-06","kind":"sale","planned":false,"acquired":false,"shares":4700,"price":43.3194,"value":203601.18,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards and certain performance restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.20 to $43.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":165259,"source":{"system":"sec-edgar","filing":"0000950170-25-002485","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017025002485/ownership.xml","form_type":"4"}},{"id":1310142,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-01-06T20:14:45.000Z","date":"2025-01-06","kind":"sale","planned":false,"acquired":false,"shares":45609,"price":42.6888,"value":1946993.4792,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards and certain performance restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.19 to $43.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":169959,"source":{"system":"sec-edgar","filing":"0000950170-25-002485","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017025002485/ownership.xml","form_type":"4"}},{"id":1310141,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-01-06T20:14:45.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":21667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2024, 33.33% of which vested on January 3, 2025 upon the achievement of a non-financial performance goal."}],"balance_after":215568,"source":{"system":"sec-edgar","filing":"0000950170-25-002485","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017025002485/ownership.xml","form_type":"4"}},{"id":1310140,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-01-06T20:14:45.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":44533,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award (\"RSU\") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2 shares acquired on November 20, 2024 pursuant to the Issuer's 2024 Employee Stock Purchase Plan."}],"balance_after":193901,"source":{"system":"sec-edgar","filing":"0000950170-25-002485","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017025002485/ownership.xml","form_type":"4"}},{"id":1309714,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70256,"kind":"person","name":"MACARTNEY LAWSON","position":1,"cik":"0001606831","reported_name":"MACARTNEY LAWSON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-06T20:14:08.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":18800,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":18800,"derivative":{"exercise_price":41.12,"exercise_date":"2026-01-02","expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":18800},"source":{"system":"sec-edgar","filing":"0000950170-25-002484","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606831/000095017025002484/ownership.xml","form_type":"4"}},{"id":1310126,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-06T20:13:34.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":18800,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":18800,"derivative":{"exercise_price":41.12,"exercise_date":"2026-01-02","expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":18800},"source":{"system":"sec-edgar","filing":"0000950170-25-002483","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000095017025002483/ownership.xml","form_type":"4"}},{"id":1309869,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":67192,"kind":"person","name":"Rowland Charles A Jr","position":1,"cik":"0001383292","reported_name":"Rowland Charles A Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-06T20:13:07.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":18800,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":18800,"derivative":{"exercise_price":41.12,"exercise_date":"2026-01-02","expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":18800},"source":{"system":"sec-edgar","filing":"0000950170-25-002482","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383292/000095017025002482/ownership.xml","form_type":"4"}},{"id":1370846,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70256,"kind":"person","name":"MACARTNEY LAWSON","position":1,"cik":"0001606831","reported_name":"MACARTNEY LAWSON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-08T18:22:28.000Z","date":"2024-11-08","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20000,"derivative":{"exercise_price":5.8,"exercise_date":"2022-01-04","expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0000950170-24-124296","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1606831/000095017024124296/ownership.xml","form_type":"4"}},{"id":1370845,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70256,"kind":"person","name":"MACARTNEY LAWSON","position":1,"cik":"0001606831","reported_name":"MACARTNEY LAWSON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-11-08T18:22:28.000Z","date":"2024-11-08","kind":"sale","planned":false,"acquired":false,"shares":2000,"price":68.6667,"value":137333.4,"ownership":{"direct":true},"balance_after":47965,"source":{"system":"sec-edgar","filing":"0000950170-24-124296","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606831/000095017024124296/ownership.xml","form_type":"4"}},{"id":1370844,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70256,"kind":"person","name":"MACARTNEY LAWSON","position":1,"cik":"0001606831","reported_name":"MACARTNEY LAWSON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-11-08T18:22:28.000Z","date":"2024-11-08","kind":"exercise","planned":false,"acquired":true,"shares":2000,"price":5.8,"value":11600.0,"ownership":{"direct":true},"balance_after":49965,"source":{"system":"sec-edgar","filing":"0000950170-24-124296","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606831/000095017024124296/ownership.xml","form_type":"4"}},{"id":1380603,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"exercise","planned":true,"acquired":false,"shares":51000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"25% of the shares subject to the option vested or will vest on each anniversary of the grant date."}],"balance_after":153000,"derivative":{"exercise_price":8.52,"exercise_date":"2024-01-03","expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":51000},"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}},{"id":1380602,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"exercise","planned":true,"acquired":false,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"One-third of the shares subject to the option vested on each anniversary of the grant date."}],"balance_after":0,"derivative":{"exercise_price":5.8,"exercise_date":"2022-01-04","expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}},{"id":1380601,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"exercise","planned":true,"acquired":false,"shares":4251,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"25% of the shares subject to the option vested on each anniversary of the grant date."}],"balance_after":0,"derivative":{"exercise_price":4.68,"exercise_date":"2021-03-31","expiration_date":"2030-03-31","underlying":"Common Stock","underlying_shares":4251},"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}},{"id":1380600,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"exercise","planned":true,"acquired":false,"shares":12750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"25% of the shares subject to the option vested on each anniversary of the grant date."}],"balance_after":0,"derivative":{"exercise_price":7.77,"exercise_date":"2021-01-03","expiration_date":"2030-01-03","underlying":"Common Stock","underlying_shares":12750},"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}},{"id":1380599,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"sale","planned":true,"acquired":false,"shares":1206,"price":81.4447,"value":98222.3082,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.35 to $81.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":149366,"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}},{"id":1380598,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"sale","planned":true,"acquired":false,"shares":7967,"price":80.6508,"value":642544.9236,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.30 to $81.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":150572,"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}},{"id":1380597,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"sale","planned":true,"acquired":false,"shares":6050,"price":79.7793,"value":482664.765,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.29 to $80.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":158539,"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}},{"id":1380596,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"sale","planned":true,"acquired":false,"shares":15825,"price":78.6907,"value":1245280.3275,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.27 to $79.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":164589,"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}},{"id":1380595,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":28007,"kind":"person","name":"ZANTE GREG","position":1,"cik":"0001264949","reported_name":"ZANTE GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-10-28T21:48:10.000Z","date":"2024-10-28","kind":"sale","planned":true,"acquired":false,"shares":23082,"price":77.6804,"value":1793018.9928,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.27 to $78.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":180414,"source":{"system":"sec-edgar","filing":"0000950170-24-117885","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1264949/000095017024117885/ownership.xml","form_type":"4"}}],"next_cursor":"2024-10-28T21:48:10.000000Z,1380595"}